- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Single centre
- Study aim: To evaluate the risk of breakthrough infection, symptomatic disease, hospitalisation, intensive care admission, and COVID-19 related death in kidney transplant recipients receiving pre-exposure prophylaxis with Tixagevimab/Cilgavimab for COVID-19 in the era of the Kraken variant
- Number of participants enrolled: 34
- Study enrolling from to
- Study includes follow-up for 6 months
Study Data
- Adults
- Elderly
- Fragile population
- Infectious diseases unit
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Tixagevimab/Cilgavimab
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to